Scientists test Radiation-Immunotherapy combo for rare bone cancer

NCT ID NCT02989636

Summary

This early-stage safety study is testing a combination treatment for chordoma, a rare bone cancer that has come back or spread. Researchers want to see if adding a targeted, high-dose radiation treatment to an immunotherapy drug (nivolumab) is safe and tolerable. The study involves a small group of patients to first understand the side effects before testing if the combination helps control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHORDOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland, 21287, United States

  • Memorial Sloan-Kettering Cancer Center

    New York, New York, 10065, United States

Conditions

Explore the condition pages connected to this study.